The sensitive role of autophagy in cancer progression

Women Have Lower Risk for Death After Resection for Lung Cancer

Restricted mean survival time difference was 0.84 years at 10 years for women undergoing pulmonary resection<strong></strong>

ALA: Lung Cancer Survival Has Increased Nationally to 22.6 Percent

People of color face worse outcomes, have lower likelihood of being diagnosed early, receiving surgery

Less Than One in 20 Eligible Adults Receives Lung Cancer Screening

Lung cancer screening at the state level does not correlate with lung cancer burden

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib

Do Not Discontinue or Delay Cancer Treatment That May Impact Survival

Use of Common Meds Tied to Lower Lung Cancer Mortality Combined use of aspirin, statins, metformin tied to lower lung cancer risk and mortality

Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression Overall survival longer than for chemotherapy in metastatic NSCLC with high PD-L1 expression

Immunotherapy Drug Atezolizumab Beats Standard Chemo for Certain Lung Cancer Patients

Lung Cancer Treatment Plans Changed Due to Pandemic – 57 percent of patients receiving active treatment had at least one change in treatment plans